Key result
Intravenous immunoglobulin added to standard management improved outcomes assessed by clinical rating scale, brain SPECT, and duration of symptomatic treatment in children with Sydenham chorea.
Why the study?
Does intravenous immunoglobulin improve outcomes in children with Sydenham chorea?
RCT (n=20)
Randomized
Does intravenous immunoglobulin improve outcomes in children with Sydenham chorea?
Intravenous immunoglobulin added to standard management may improve clinical and imaging outcomes in children with Sydenham chorea.
May warrant adding IVIG to standard care in pediatric Sydenham chorea; provides RCT evidence supporting immunomodulation.
Sydenham chorea is a post-streptococcal, autoimmune, neuropsychiatric, movement disorder. There is no effective treatment. In a randomized study, comparison was made of the outcomes of 10 children treated with standard management alone compared to 10 who received additional intravenous immunoglobulin. The outcomes were assessed using a clinical rating scale, brain single-photon emission computed tomography, and the duration of symptomatic treatment. All three outcome measurement tools found improved outcomes in the group that received intravenous immunoglobulin.
No takes yet. Share an insight, caveat, or question.
Walker et al. (2011) conducted an RCT in Sydenham chorea (n=20). Intravenous immunoglobulin vs. Standard management alone was evaluated on Clinical rating scale, brain single-photon emission computed tomography, and the duration of symptomatic treatment. Intravenous immunoglobulin added to standard management improved outcomes assessed by clinical rating scale, brain SPECT, and duration of symptomatic treatment in children with Sydenham chorea.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: